15
Participants
Start Date
February 20, 2023
Primary Completion Date
February 28, 2024
Study Completion Date
November 6, 2024
Sanofi-GSK monovalent (B.1.351) CoV2 preS dTM-AS03 COVID-19 vaccine
0.5 mL per dose of the Sanofi-GSK COVID-19 Vaccine will be administered intramuscularly in the deltoid muscle of the upper arm
Johns Hopkins Institute for Clinical and Translational Research: Broadway Adult Outpatient Clinical Research Unit, Baltimore
Emory University School of Medicine: Transplantation, Atlanta
University of Wisconsin School of Medicine and Public Health: Transplantation, Madison
University of Illinois Medical Center: Transplantation, Chicago
University of California San Diego Medical Center: Transplantation, San Diego
UCSF School of Medicine: Transplantation, San Francisco
Collaborators (1)
PPD Development, LP
INDUSTRY
Johns Hopkins University
OTHER
Sanofi Pasteur, a Sanofi Company
INDUSTRY
National Institute of Allergy and Infectious Diseases (NIAID)
NIH